Invention Application
- Patent Title: ANTICANCER COMPOSITION COMPRISING TLR5 AGONIST DERIVED FROM FLAGELLIN AS ACTIVE INGREDIENT
-
Application No.: US17789300Application Date: 2021-05-07
-
Publication No.: US20220389065A1Publication Date: 2022-12-08
- Inventor: Seok-Goo CHO , Keon-IL IM , Nayoun KIM , Young-Woo JEON , Yunejin SONG , Junseok LEE
- Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Applicant Address: KR Seoul
- Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee Address: KR Seoul
- Priority: KR10-2020-0067728 20200604
- International Application: PCT/KR2021/005734 WO 20210507
- Main IPC: C07K14/195
- IPC: C07K14/195 ; A61K38/16 ; C07K16/28
Abstract:
The present invention relates to an anticancer drug composition comprising, as an active ingredient, TLR5 agonist derived from flagellin. The TLR5 agonist derived from flagellin of the present invention can exhibit an anticancer or anticancer adjuvant effect alone or concurrently with an immune checkpoint blockade, and thus, can be developed as a cancer cell growth inhibitory active ingredient.
Information query
